<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25101989</article-id>
      <article-id pub-id-type="pmc">4602446</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000000054</article-id>
      <article-id pub-id-type="art-access-id">00054</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Crohn&#x2019;s Disease Successfully Treated With Infliximab in a Patient Receiving Hemodialysis: Case Report and Review of the Literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chiba</surname>
            <given-names>Mitsuro</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsuda</surname>
            <given-names>Satoko</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsuji</surname>
            <given-names>Tsuyotoshi</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakane</surname>
            <given-names>Kunio</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Komatsu</surname>
            <given-names>Masafumi</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miura</surname>
            <given-names>Yoshiko</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishida</surname>
            <given-names>Toshiya</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shibahara</surname>
            <given-names>Toru</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nishimoto</surname>
            <given-names>Tadashi</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Guidi</surname>
            <given-names>Luisa</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>Division of Gastroenterology (MC, ST, TT, KN, MK), Division of Urology (YM, TI), and Division of Cardiology (TS), Akita City Hospital; Akita South Clinic (TN), Akita City, Japan.</aff>
      <author-notes>
        <corresp>Correspondence: Mitsuro Chiba, MD, Division of Gastroenterology, Akita City Hospital, 4-30, Matsuoka-machi, Akita City 010-0933, Japan (e-mail: acd00517nullakita-city-hp.jp).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <volume>93</volume>
      <issue>7</issue>
      <elocation-id>e54</elocation-id>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>19</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>6</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2014 Wolters Kluwer Health | Lippincott Williams &amp; Wilkins</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nd/4.0">
          <license-p>This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nd/4.0">http://creativecommons.org/licenses/by-nd/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-93-e54.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>There is limited information in the use of antitumor necrosis factor &#x3B1;, infliximab, in patients on hemodialysis. In Crohn&#x2019;s disease (CD), only 3 cases are reported.</p>
        <p>A 76-year-old man on hemodialysis for renal failure caused by immunoglobulin A nephropathy developed diarrhea and abdominal pains. A marked edema was observed in the pretibia and ankle. An increase of C-reactive protein (CRP) and erythrocyte sedimentation rate, hypoalbuminemia, hypocholesterolemia, and moderate anemia was found. Ultrasonography and computed tomography (CT) found wall thickness in the left colon. Sigmoidoscopy revealed multiple ulcers in the sigmoid colon and noncaseating epithelioid granuloma was found in the biopsy specimen. Barium enema study exhibited collar button signs and longitudinal ulcers in the left colon.</p>
        <p>A severe form of CD was diagnosed. Metronidazole seemed to decrease CRP but was ineffective in ameliorating diarrhea. Infliximab rather than steroid hormone was chosen for the treatment. Standard induction therapy with infliximab was initiated. Symptoms rapidly improved then disappeared. CD activity index decreased from 747 to a remission level of 134 after 2 infusions of infliximab. Scheduled maintenance infliximab therapy was administered after the induction therapy. Ultrasonography and CT showed a disappearance of the wall thickness of the colon. Adverse reactions were not observed.</p>
        <p>Infliximab was effective and safe in a patient with CD on hemodialysis. Our case has added additional literature in accordance with previous reports supporting infliximab as effective and safe in patients on hemodialysis.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The efficacy of antitumor necrosis factor &#x3B1; (TNF-&#x3B1;), infliximab, has been shown to be effective in various disease treatment including Crohn&#x2019;s disease (CD).<sup><xref rid="R1" ref-type="bibr">1</xref></sup> However, there is limited information in the use of infliximab in patients on hemodialysis. Although the highest incidence in CD is among younger generations, 10&#x2013;30 years old, older people are also affected.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Here we report a case of an old man on hemodialysis who developed CD and was successfully treated with infliximab.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 76-year-old man, 166&#x2009;cm tall and weighing 47.1&#x2009;kg, receiving hemodialysis for 6 years was referred to our Division of Gastroenterology, Akita City Hospital, Akita City, Japan, in the middle of November 2013, because of diarrhea, abdominal pain, and fever for 1 week. Hematochezia was absent. He was diagnosed with Wolff-Parkinson-White syndrome in 1973, paroxysmal atrial fibrillation in 1982, myocardial infarction in 1993, and immunoglobulin A (IgA) nephropathy in 2005. IgA nephropathy resulted in renal failure leading to hemodialysis thrice a week since 2007. Tenderness in the left lower abdomen and a marked edema in both sides of the pretibia and ankle were observed. Laboratory data were as follows: an increase of C-reactive protein (CRP), 10.73&#x2009;mg/dL (normal range &#x2264;0.19); an increase of erythrocyte sedimentation rate, 46&#x2009;mm/h; hypoalbuminemia, 2.0&#x2009;g/dL; hypocholesterolemia, 107&#x2009;mg/dL; and moderate anemia, hemoglobin 9.0&#x2009;g/dL (Figure <xref ref-type="fig" rid="F1">1</xref>). Ultrasonography and computed tomography (CT) found wall thickness in continuous form in the left colon. Sigmoidoscopy revealed multiple irregular-shaped ulcers in the sigmoid colon (Figure <xref ref-type="fig" rid="F2">2</xref>). Barium enema study exhibited collar button ulcers, longitudinal ulcers, and coarse mucosa in the left colon (Figure <xref ref-type="fig" rid="F3">3</xref>). Negative results were obtained in the following tests: cytomegalovirus antigenemia, stool culture, and <italic>Clostridium difficile</italic> toxin. Neither inclusion body nor immunohistologic cytomegalovirus positive cell was found in the biopsy specimen. Neither ghost tubules nor subepithelial collagen thickening were observed. But noncaseating epithelioid granuloma was found. Therefore, a severe form of CD was diagnosed.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> Metronidazole seemed to decrease CRP but was ineffective in ameliorating diarrhea. Rapid efficacy of infliximab in CD<sup><xref rid="R4" ref-type="bibr">4</xref></sup> and reports of safety of infliximab in patients on hemodialysis<sup><xref rid="R5" ref-type="bibr">5</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref></sup> encouraged us and our patient to use infliximab rather than steroid hormone that has an adverse osteoporotic effect. Latent tuberculosis was excluded by normal roentgenogram of the chest and negative Elispot assay for <italic>Mycobacterium tuberculosis</italic>.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Hepatitis B infection was also excluded by negative test in surface antigen, surface antibody, and core antibody.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Written informed consent on the use of infliximab and publishing the study was obtained. The standard induction therapy (3 infusions at week 0, 2, and 6) of infliximab (300&#x2009;mg) was initiated.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Infliximab was infused on alternative days to hemodialysis. Symptoms rapidly improved then disappeared. Crohn&#x2019;s disease activity index (CDAI) decreased from 747 to a remission level (less than 150) of 134<sup><xref rid="R3" ref-type="bibr">3</xref></sup> after 2 infusions of infliximab. CRP became normal and increase of albumin was ascertained before discharge (Figure <xref ref-type="fig" rid="F1">1</xref>). A third infusion of infliximab was administered as planned (Figure <xref ref-type="fig" rid="F1">1</xref>). Although albumin was further increased to 2.9&#x2009;g/dL, fecal occult blood was more than 1000&#x2009;ng/mL (Figure <xref ref-type="fig" rid="F1">1</xref>) indicating that there is still active inflammation in the intestine. Scheduled maintenance infliximab therapy<sup><xref rid="R15" ref-type="bibr">15</xref></sup> was administered. An easy tendency to arrhythmia and tachycardia and renal failure hampered invasive morphological studies of the bowel after the standard induction therapy. Noninvasive studies with ultrasonography and CT found a disappearance of the wall thickness of the colon. Adverse reactions of infliximab were not observed during the course.</p>
      <fig id="F1" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Clinical course. CRP (normal range &#x2264;0.19&#x2009;mg/dL); ESR (&#x2264;10&#x2009;mm/h); fecal occult blood (&lt;100&#x2009;ng/mL); T chol (&#x2265;120 to &#x2264;220&#x2009;mg/dL). CDAI&#x2009;=&#x2009;Crohn&#x2019;s disease activity index; CRP&#x2009;=&#x2009;C-reactive protein; ESR&#x2009;=&#x2009;erythrocyte sedimentation rate; IFX&#x2009;=&#x2009;infliximab; T chol&#x2009;=&#x2009;total cholesterol.</p>
        </caption>
        <graphic xlink:href="medi-93-e54-g001"/>
      </fig>
      <fig id="F2" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Endoscopic pictures of sigmoidoscopy. Inflamed mucosa with (A) multiple irregular-shaped ulcers (arrow) and (B) punched-out ulcer (arrow) was observed in the sigmoid colon.</p>
        </caption>
        <graphic xlink:href="medi-93-e54-g002"/>
      </fig>
      <fig id="F3" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Radiograph of barium enema study. Clear collar button signs were observed in the (A) sigmoid colon (arrows) and the (B) descending colon (short arrows). Long fine arrows in (B) show calcification of the aorta.</p>
        </caption>
        <graphic xlink:href="medi-93-e54-g003"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Collar button signs and longitudinal ulcers are observed in both CD and ulcerative colitis.<sup><xref rid="R16" ref-type="bibr">16</xref>&#x2013;<xref rid="R18" ref-type="bibr">18</xref></sup> In the present case, an absent hematochezia and a positive noncaseating epithelioid granuloma led to a diagnosis of CD.</p>
      <p>Biologic agents revolutionized treatment in medicine. TNF-&#x3B1; is a key molecule of the inflammatory response and is involved in the pathogenesis of various autoimmune and noninfectious inflammatory conditions. TNF-&#x3B1; antagonists have been shown to be effective in CD, ulcerative colitis, rheumatoid arthritis, Behcet&#x2019;s disease, ankylosing spondylitis, uveitis, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> In CD, TNF-&#x3B1; antagonists are effective in inducing and maintaining remission,<sup><xref rid="R15" ref-type="bibr">15</xref></sup> systemic complications such as pyoderma gangrenosum and arthritis,<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> and secondary amyloidosis.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Infliximab was the first biologic agent approved in Japan for CD in 2002 and for rheumatoid arthritis in 2003. There are very few reports on the use of infliximab in patients on dialysis: rheumatoid arthritis,<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> ankylosing spondylitis,<sup><xref rid="R9" ref-type="bibr">9</xref></sup> sarcoidosis,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> and psoriatic arthritis.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> In CD, 3 case reports are available and all are from Japan.<sup><xref rid="R10" ref-type="bibr">10</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref></sup> In these reports, CD was first diagnosed followed by renal failure resulting in hemodialysis. Infliximab was used for enterocutaneous fistula,<sup><xref rid="R10" ref-type="bibr">10</xref></sup> relapse of CD,<sup><xref rid="R11" ref-type="bibr">11</xref></sup> and uncontrolled activity with conventional treatment.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Conventional treatment such as 5-aminosalicylate and steroid hormone was also ineffective in the former 2 cases.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref></sup> Therefore, in all the 3 cases of CD, infliximab was used after conventional therapy. Infliximab was effective in these patients including CD.<sup><xref rid="R5" ref-type="bibr">5</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref></sup> Adverse effects were described in 3 cases: postinfusion transient itching,<sup><xref rid="R7" ref-type="bibr">7</xref></sup> deep vein thrombosis,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> and pneumocystis jivoreci pneumonia.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> The latter 2 hampered the succession of infliximab treatment. Except for these 2 cases, scheduled infliximab maintenance therapy was administered in these diseases.<sup><xref rid="R6" ref-type="bibr">6</xref>&#x2013;<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup> Needless to say, attention to be paid to a variety of adverse events associated with infliximab.<sup><xref rid="R22" ref-type="bibr">22</xref>&#x2013;<xref rid="R25" ref-type="bibr">25</xref></sup> Pharmacokinetics of TNF-&#x3B1; antagonists in patients on dialysis is not known. However, Kume et al,<sup><xref rid="R12" ref-type="bibr">12</xref></sup> in CD, measured the serum concentration of infliximab before and after hemodialysis and showed that the serum level of infliximab was essentially unchanged by hemodialysis. In our case, CD appeared in a patient on hemodialysis. No adverse event of infliximab was encountered.</p>
      <p>The number of patients on regular dialysis treatment in Japan is steadily increasing: 103,296 in 1990, 206,134 in 2000, and 309,946 in 2012.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> The primary disease for dialysis is diabetic nephropathy holding the first place since 1998 accounting for 44.1% followed by chronic glomerulonephritis in the second place (19.4%). The mean age for initiation of hemodialysis is 68.4 years.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> The number of patients with CD is also steadily increasing in Japan: 6609 in 1990, 19,651 in 2000, and 36,418 in 2012.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Both diabetes mellitus and CD are popular in wealthy nations and they are not restricted to western countries anymore but distributed worldwide and known as global diseases.<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> It is anticipated that the number of CD patient on dialysis will increase in the future not only in Japan but also worldwide.</p>
      <p>Our case has contributed additional literature in accordance with previous reports supporting infliximab as effective and safe in patients on hemodialysis.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviation CD = Crohn&#x2019;s disease, CDAI = Crohn&#x2019;s disease activity index, CRP = C-reactive protein, CT = computed tomography, ESR = erythrocyte sedimentation rate, IFX = infliximab, T chol = total cholesterol, TNF-&#x3B1; = TNF-&#x3B1;tumor necrosis factor &#x3B1;</p>
      </fn>
      <fn fn-type="conflict">
        <p>The authors have no funding and conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karampetsou</surname><given-names>MP</given-names></name><name><surname>Liossis</surname><given-names>SN</given-names></name><name><surname>Sfikakis</surname><given-names>PP</given-names></name></person-group>
<article-title>TNF-&#x3B1; antagonists beyond approved indications: stories of success and prospects for future</article-title>. <source>QJM</source>. <year>2010</year>;<volume>103</volume>:<fpage>917</fpage>&#x2013;<lpage>928</lpage>.<pub-id pub-id-type="pmid">20802008</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tokayer</surname><given-names>AZ</given-names></name><name><surname>Brandt</surname><given-names>LJ</given-names></name></person-group>
<article-title>Idiopathic inflammatory bowel diseases in the elderly</article-title>. In: <source>Inflammatory Bowel Disease</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>W.B. Saunders</publisher-name>; <year>2000</year>:<fpage>335</fpage>&#x2013;<lpage>341</lpage>.</mixed-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtenstein</surname><given-names>GR</given-names></name><name><surname>Hanauer</surname><given-names>SB</given-names></name><name><surname>Sandborn</surname><given-names>WJ</given-names></name></person-group>
<article-title>The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn&#x2019;s disease in adults</article-title>. <source>Am J Gastroenterol</source>. <year>2009</year>;<volume>104</volume>:<fpage>465</fpage>&#x2013;<lpage>483</lpage>.<pub-id pub-id-type="pmid">19174807</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>M</given-names></name><name><surname>Sugawara</surname><given-names>T</given-names></name><name><surname>Tsuda</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Esophageal ulcer of Crohn&#x2019;s disease: disappearance in 1 week with infliximab</article-title>. <source>Inflamm Bowel Dis</source>. <year>2009</year>;<volume>15</volume>:<fpage>1121</fpage>&#x2013;<lpage>1122</lpage>.<pub-id pub-id-type="pmid">18942761</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>AM</given-names></name><name><surname>Pochapin</surname><given-names>MB</given-names></name></person-group>
<article-title>Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy</article-title>. <source>Ann Intern Med</source>. <year>2001</year>;<volume>135</volume>:<fpage>27</fpage>&#x2013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">11434729</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Cuchacovich</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis</article-title>. <source>J Rheumatol</source>. <year>2002</year>;<volume>29</volume>:<fpage>636</fpage>&#x2013;<lpage>637</lpage>.<pub-id pub-id-type="pmid">11908584</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammoudeh</surname><given-names>M</given-names></name></person-group>
<article-title>Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis</article-title>. <source>Rheumatology</source>. <year>2006</year>;<volume>45</volume>:<fpage>357</fpage>&#x2013;<lpage>359</lpage>.<pub-id pub-id-type="pmid">16368727</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saougou</surname><given-names>I</given-names></name><name><surname>Papagoras</surname><given-names>C</given-names></name><name><surname>Markatseli</surname><given-names>TE</given-names></name><etal/></person-group>
<article-title>A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review</article-title>. <source>Clin Rheumatol</source>. <year>2010</year>;<volume>29</volume>:<fpage>1455</fpage>&#x2013;<lpage>1459</lpage>.<pub-id pub-id-type="pmid">20490588</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marocchi</surname><given-names>E</given-names></name><name><surname>Spadaro</surname><given-names>A</given-names></name><name><surname>Giannakakis</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Infliximab in a patient with ankylosing spondylitis and secondary IgA nephropathy requiring haemodialysis</article-title>. <source>Clin Exp Rheumatol</source>. <year>2010</year>;<volume>28</volume>:<fpage>440</fpage>.<pub-id pub-id-type="pmid">20576230</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>H</given-names></name></person-group>
<article-title>Infliximab treatment of a patient on hemodialysis with fistulating Crohn&#x2019;s disease: the Japanese experience. Shinyaku To Rinsho (in Japanese, abstract in English)</article-title>. <source>J New Rem Clin</source>. <year>2007</year>;<volume>56</volume>:<fpage>675</fpage>&#x2013;<lpage>680</lpage>.</mixed-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>H</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Koyanagi</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Infliximab treatment in a hemodialysis patient with relapse of Crohn&#x2019;s disease after a 40-year interval. Nihon Tohseki Igakukai Zashi (in Japanese, abstract in English)</article-title>. <source>J Jpn Soc Dial Ther</source>. <year>2009</year>;<volume>42</volume>:<fpage>905</fpage>&#x2013;<lpage>911</lpage>.</mixed-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kume</surname><given-names>K</given-names></name><name><surname>Yamasaki</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Infliximab treatment in a patient with Crohn&#x2019;s disease on haemodialysis</article-title>. <source>Colorectal Dis</source>. <year>2011</year>;<volume>13</volume>:<fpage>341</fpage>.<pub-id pub-id-type="pmid">20082632</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>BP</given-names></name><name><surname>Doherty</surname><given-names>GA</given-names></name><name><surname>Gautam</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy</article-title>. <source>Inflamm Bowel Dis</source>. <year>2012</year>;<volume>18</volume>:<fpage>1057</fpage>&#x2013;<lpage>1063</lpage>.<pub-id pub-id-type="pmid">21953829</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandborn</surname><given-names>WJ</given-names></name><name><surname>Hanauer</surname><given-names>SB</given-names></name></person-group>
<article-title>Infliximab in the treatment of Crohn&#x2019;s disease: a user&#x2019;s guide for clinicians</article-title>. <source>Am J Gastroenterol</source>. <year>2002</year>;<volume>97</volume>:<fpage>2962</fpage>&#x2013;<lpage>2972</lpage>.<pub-id pub-id-type="pmid">12492177</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombel</surname><given-names>JF</given-names></name><name><surname>Sandborn</surname><given-names>WJ</given-names></name><name><surname>Reinisch</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Infliximab, azathioprine, or combination therapy for Crohn&#x2019;s disease</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>362</volume>:<fpage>1383</fpage>&#x2013;<lpage>1395</lpage>.<pub-id pub-id-type="pmid">20393175</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margulis</surname><given-names>AR</given-names></name><name><surname>Goldberg</surname><given-names>HI</given-names></name><name><surname>Lawson</surname><given-names>TL</given-names></name><etal/></person-group>
<article-title>The overlapping spectrum of ulcerative and granulomatous colitis: a roentgenographic-pathologic study</article-title>. <source>Am J Roent Rad Ther Nucl Med</source>. <year>1971</year>;<volume>113</volume>:<fpage>325</fpage>&#x2013;<lpage>334</lpage>.</mixed-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtenstein</surname><given-names>JE</given-names></name><name><surname>Madewell</surname><given-names>JE</given-names></name><name><surname>Feigin</surname><given-names>DS</given-names></name></person-group>
<article-title>The Collar button ulcer A radiologic&#x2013;pathologic correlation</article-title>. <source>Gastrointest Radiol</source>. <year>1979</year>;<volume>4</volume>:<fpage>79</fpage>&#x2013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">761749</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>T</given-names></name><name><surname>Takei</surname><given-names>S</given-names></name><name><surname>Nozawa</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A case of ulcerative colitis associated with longitudinal ulcers (in Japanese, abstract in English)</article-title>. <source>Endosc Forum Dig Dis</source>. <year>1996</year>;<volume>12</volume>:<fpage>248</fpage>&#x2013;<lpage>252</lpage>.</mixed-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooklyn</surname><given-names>TN</given-names></name><name><surname>Dunnill</surname><given-names>MGS</given-names></name><name><surname>Shetty</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial</article-title>. <source>Gut</source>. <year>2006</year>;<volume>55</volume>:<fpage>505</fpage>&#x2013;<lpage>509</lpage>.<pub-id pub-id-type="pmid">16188920</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>I</given-names></name><name><surname>Caspi</surname><given-names>D</given-names></name><name><surname>Yeshurun</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The effect of infliximab on extraintestinal manifestations of Crohn&#x2019;s disease</article-title>. <source>Rheumatol Int</source>. <year>2004</year>;<volume>25</volume>:<fpage>406</fpage>&#x2013;<lpage>410</lpage>.<pub-id pub-id-type="pmid">15309501</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pukitis</surname><given-names>A</given-names></name><name><surname>Zake</surname><given-names>T</given-names></name><name><surname>Groma</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn&#x2019;s disease: case report and review of the literature</article-title>. <source>J Gastrointestin Liver Dis</source>. <year>2013</year>;<volume>22</volume>:<fpage>333</fpage>&#x2013;<lpage>336</lpage>.<pub-id pub-id-type="pmid">24078992</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>N</given-names></name><name><surname>Mahl</surname><given-names>TC</given-names></name></person-group>
<article-title>Pneumocystis jivoreci (carinii) pneumonia after infliximab therapy: a review of 84 cases</article-title>. <source>Dig Dis Sci</source>. <year>2007</year>;<volume>52</volume>:<fpage>1481</fpage>&#x2013;<lpage>1484</lpage>.<pub-id pub-id-type="pmid">17429728</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Peyrin-Biroulet</surname><given-names>L</given-names></name></person-group>
<article-title>Opportunistic infections with anti-tumor necrosis factor-&#x3B1; therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials</article-title>. <source>Am J Gastroenterol</source>. <year>2013</year>;<volume>108</volume>:<fpage>1268</fpage>&#x2013;<lpage>1276</lpage>.<pub-id pub-id-type="pmid">23649185</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerbleski</surname><given-names>JF</given-names></name><name><surname>Gottlieb</surname><given-names>AB</given-names></name></person-group>
<article-title>Dermatological complications and safety of anti-TNF treatments</article-title>. <source>Gut</source>. <year>2009</year>;<volume>58</volume>:<fpage>1033</fpage>&#x2013;<lpage>1039</lpage>.<pub-id pub-id-type="pmid">19592682</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bessissow</surname><given-names>T</given-names></name><name><surname>Renard</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Review article: non-malignant haematological complications of anti-tumor necrosis factor alpha therapy</article-title>. <source>Aliment Phamacol Ther</source>. <year>2012</year>;<volume>36</volume>:<fpage>312</fpage>&#x2013;<lpage>323</lpage>.</mixed-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <mixed-citation publication-type="book">
<collab>Japanese Society for Dialysis Therapy</collab>. <source>An overview of regular dialysis treatment in Japan as of Dec. 31, 2012</source>. <year>2014</year>
<comment><ext-link ext-link-type="uri" xlink:href="http://docs.jsdt.or.jp/overview/index.html">http://docs.jsdt.or.jp/overview/index.html</ext-link></comment>
<date-in-citation>Accessed February 6, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <mixed-citation publication-type="book"><collab>The Ministry of Health, Welfare, and Labor, Japan</collab>. <source>Japan Intractable Diseases Information Center</source>. <year>2014</year>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.nanbyou.or.jp/entry/1356">http://www.nanbyou.or.jp/entry/1356</ext-link></comment>
<date-in-citation>Accessed February 19, 2014</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molodecky</surname><given-names>NA</given-names></name><name><surname>Soon</surname><given-names>IS</given-names></name><name><surname>Rabi</surname><given-names>DM</given-names></name><etal/></person-group>
<article-title>Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systemic review</article-title>. <source>Gastroenterology</source>. <year>2012</year>;<volume>142</volume>:<fpage>46</fpage>&#x2013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">22001864</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danaei</surname><given-names>G</given-names></name><name><surname>Finucane</surname><given-names>MM</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>378</volume>:<fpage>31</fpage>&#x2013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">21705069</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
